Combined Immune Therapy for the Treatment of Visceral Leishmaniasis
暂无分享,去创建一个
R. Kumar | S. Sundar | A. Haque | M. Montes de Oca | F. Amante | M. Sheel | Rebecca J. Faleiro | Patrick T. Bunn | S. Best | L. Beattie | Susanna S. Ng | Chelsea L Edwards | C. Engwerda | S. Chauhan | D. Sacks | S. Nylén | L. Hafner | Neetu Singh | Lynette Beattie | Chelsea L. Edwards
[1] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[2] Peter D. Crompton,et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. , 2015, Cell host & microbe.
[3] P. Sharma,et al. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.
[4] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[5] R. Kumar,et al. Leishmania Specific CD4 T Cells Release IFNγ That Limits Parasite Replication in Patients with Visceral Leishmaniasis , 2014, PLoS neglected tropical diseases.
[6] J. Wolchok,et al. Immune modulation for cancer therapy , 2014, British Journal of Cancer.
[7] Patrick T. Bunn,et al. The Regulation of CD4+ T Cell Responses during Protozoan Infections , 2014, Front. Immunol..
[8] P. Kaye,et al. Tissue Requirements for Establishing Long-Term CD4+ T Cell–Mediated Immunity following Leishmania donovani Infection , 2014, The Journal of Immunology.
[9] R. Kumar,et al. Leishmania specific CD4 T cells release IFN-γ that limits parasite replication in patients with visceral leishmaniasis , 2014 .
[10] Peter D. Crompton,et al. Exposure-Dependent Control of Malaria-Induced Inflammation in Children , 2014, PLoS pathogens.
[11] R. Kumar,et al. Immune Regulation during Chronic Visceral Leishmaniasis , 2014, PLoS neglected tropical diseases.
[12] Daniel Argaw,et al. Visceral Leishmaniasis Outbreak in South Sudan 2009–2012: Epidemiological Assessment and Impact of a Multisectoral Response , 2014, PLoS neglected tropical diseases.
[13] S. Sundar,et al. Risk Factors for Visceral Leishmaniasis and Asymptomatic Leishmania donovani Infection in India and Nepal , 2014, PloS one.
[14] Peter G. Smith,et al. Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial , 2014, PLoS neglected tropical diseases.
[15] M. Feeney,et al. IFNγ/IL-10 Co-producing Cells Dominate the CD4 Response to Malaria in Highly Exposed Children , 2014, PLoS pathogens.
[16] Eric W. Cross,et al. T cell responses: naive to memory and everything in between. , 2013, Advances in physiology education.
[17] Douglas E. Jones,et al. Programmed Death 1–Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Function , 2013, The Journal of Immunology.
[18] P. Ascierto,et al. Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination , 2013, Clinical Cancer Research.
[19] S. Sundar,et al. Leishmaniasis: an update of current pharmacotherapy , 2013, Expert opinion on pharmacotherapy.
[20] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[21] P. Klenerman. Faculty Opinions recommendation of Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. , 2012 .
[22] E. Yang,et al. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets , 2011, Nature Immunology.
[23] R. Kumar,et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. , 2011, The Journal of infectious diseases.
[24] P. Kaye,et al. Critical Roles for LIGHT and Its Receptors in Generating T Cell-Mediated Immunity during Leishmania donovani Infection , 2011, PLoS pathogens.
[25] S. Stäger,et al. Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani , 2011, Journal of tropical medicine.
[26] R. Kumar,et al. IL-27 and IL-21 Are Associated with T Cell IL-10 Responses in Human Visceral Leishmaniasis , 2011, The Journal of Immunology.
[27] S. Sundar,et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial , 2011, The Lancet.
[28] B. Saha,et al. CD40 Expression Levels Modulate Regulatory T Cells in Leishmania donovani Infection , 2010, The Journal of Immunology.
[29] L. Vaickus,et al. Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR. , 2010 .
[30] Shyam Sundar,et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. , 2010, The New England journal of medicine.
[31] V. Yardley,et al. Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+ T Cell Responses Enhances Antiparasitic Immunity , 2010, The Journal of Immunology.
[32] Margarida Saraiva,et al. The regulation of IL-10 production by immune cells , 2010, Nature Reviews Immunology.
[33] S. Henson,et al. KLRG1—more than a marker for T cell senescence , 2009, AGE.
[34] Jane E. Dalton,et al. VCAM-1 and VLA-4 Modulate Dendritic Cell IL-12p40 Production in Experimental Visceral Leishmaniasis , 2008, PLoS pathogens.
[35] D. Pellicci,et al. Activation of Invariant NKT Cells Exacerbates Experimental Visceral Leishmaniasis , 2008, PLoS pathogens.
[36] S. Sundar,et al. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis , 2007, The Journal of experimental medicine.
[37] C. Engwerda,et al. Balancing immunity and pathology in visceral leishmaniasis , 2007, Immunology and cell biology.
[38] T. Nomura,et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.
[39] H. Murray. Prevention of Relapse after Chemotherapy in a Chronic Intracellular Infection: Mechanisms in Experimental Visceral Leishmaniasis1 , 2005, The Journal of Immunology.
[40] A. Awasthi,et al. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses , 2004, Nature Medicine.
[41] P. Kaye,et al. Immunotherapy with OX40L‐Fc or anti‐CTLA‐4 enhances local tissue responses and killing of Leishmania donovani , 2004, European journal of immunology.
[42] S. Schultz-Cherry,et al. Activation of TGF-β by Leishmania chagasi: Importance for Parasite Survival in Macrophages 1 , 2003, The Journal of Immunology.
[43] D. Voehringer,et al. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). , 2002, Blood.
[44] L. Abel,et al. The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. , 2002, Microbes and infection.
[45] R. Coffman,et al. Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy , 2002, Infection and Immunity.
[46] C. Hunter,et al. IL‐10 mediates susceptibility to Leishmania donovani infection , 2001, European journal of immunology.
[47] H. Murray,et al. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. , 2000, The Journal of infectious diseases.
[48] P. Kaye,et al. Organ-specific immune responses associated with infectious disease. , 2000, Immunology today.
[49] A. Sette,et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. , 1999, Journal of immunology.
[50] P. Kaye,et al. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. , 1998, Journal of immunology.
[51] Y. Liu,et al. IL‐10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3‐dependent and ‐independent pathways , 1998, The EMBO journal.
[52] K. Welte,et al. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. , 1987, Journal of immunology.
[53] D. Sacks,et al. An analysis of T cell responsiveness in Indian kala-azar. , 1987, Journal of immunology.
[54] F. Liew,et al. IMMUNE RESPONSE TO CHEMICALLY MODIFIED FLAGELLIN III. ENHANCED CELL-MEDIATED IMMUNITY DURING HIGH AND LOW ZONE ANTIBODY TOLERANCE TO FLAGELLIN , 1972 .
[55] C. Parish,et al. IMMUNE RESPONSE TO CHEMICALLY MODIFIED FLAGELLIN , 1971, The Journal of experimental medicine.
[56] C. Hunter,et al. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. , 2006, The American journal of pathology.
[57] D. Smith,et al. Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[58] C. Parish. Immune response to chemically modified flagellin. IV. Further studies on the relationship between humoral and cell-mediated immunity. , 1973, Cellular immunology.